Every Form 4 that MIRA Pharmaceuticals, Inc. (MIRA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MIRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MIRA filings page.
MIRA PHARMACEUTICALS, INC. director Matthew Paul Del Giudice reported receiving a grant of stock options. He was awarded 50,000 stock options to buy common stock at an exercise price of $0.94 per share, expiring on June 12, 2036.
The options were granted under the company’s 2022 Omnibus Incentive Plan. According to the vesting schedule, 50% of the options vest six months after the June 12, 2026 grant date, and the remaining half vests on the one-year anniversary of that date.
MIRA PHARMACEUTICALS, INC. director Matthew Pratt received a grant of stock options as equity compensation. He was awarded 50,000 stock options for common stock at an exercise price of $0.94 per share, equal to the closing price on June 12, 2026.
The options were granted under the company’s 2022 Omnibus Incentive Plan. Half of the options vest six months after the grant date and the remaining half vest one year after the grant date. Following this award, the filing shows Pratt holding 50,000 stock options directly, which expire on June 12, 2036.
MIRA PHARMACEUTICALS, INC. director Edward Clouston MacPherson received a grant of 50,000 stock options for common stock. The options have an exercise price of $0.94 per share and expire on June 12, 2036.
According to the grant terms, 50% of the options vest on the six-month anniversary of the June 12, 2026 grant date, and the remaining 50% vest on the one-year anniversary. Following this award, he holds 50,000 stock options directly.
MIRA PHARMACEUTICALS, INC. reported that director Shekhat Denil Nanji received a grant of stock options to buy 50,000 shares of common stock at an exercise price of $0.94 per share on June 12, 2026. The options were granted under the company’s 2022 Omnibus Incentive Plan as compensation, not as an open‑market purchase.
According to the grant terms, 50% of the options vest six months after the grant date and the remaining 50% vest one year after the grant date. The options expire on June 12, 2036 if not exercised. After this award, Nanji holds 50,000 stock options directly.
MIRA PHARMACEUTICALS, INC. reported an equity compensation award to its Chief Executive Officer, Erez Aminov. On March 30, 2026, he was granted 83,500 restricted stock units (RSUs), each representing the right to receive one share of common stock.
The footnotes state that all of these RSUs vested on the grant date, meaning the award became fully earned immediately. Following this grant, Aminov held 83,500 RSUs directly, with an expiration date of March 30, 2036. This is a compensation-related acquisition, not an open-market stock purchase or sale.
Denil Shekhat, a director of MIRA PHARMACEUTICALS, INC. (MIRA), reported on Form 4 that on 10/01/2025 she acquired 22,378 restricted shares of the issuer's common stock at a price of $1.35 per share. The filing shows the shares were issued as compensation in connection with the issuer's acquisition of SKNY Pharmaceuticals, Inc. Following the transaction the reporting person beneficially owns 22,378 shares in a direct ownership form. The Form 4 was signed on 10/03/2025 and was filed by one reporting person.
Erez Aminov, who is listed as both Chief Executive Officer and a Director of Mira Pharmaceuticals, Inc. (MIRA), reported an acquisition of 2,685,456 restricted shares of the issuer's common stock on 10/01/2025. The filing shows 3,530,156 shares beneficially owned following the transaction, held in a direct ownership form. The restricted shares were issued as compensation to Mira in connection with the company’s acquisition of SKNY Pharmaceuticals, Inc., per the explanatory note. The Form 4 is signed by Mr. Aminov on 10/03/2025.